Esketamine — Spravato — broke the most stubborn rule in antidepressant pharmacology: that the therapeutic effect takes weeks. The FDA approved it in 2019 for treatment-resistant depression, and shortly after for major depression with acute suicidal ideation. It works within hours. The mechanism is fundamentally different from every monoamine-based antidepressant before it.
- Class
- NMDA glutamate receptor antagonist
- Mechanism
- Non-competitive NMDA receptor antagonism → glutamate surge → rapid synaptogenesis and AMPA receptor signaling
- Typical dose
- 56-84 mg intranasal, twice weekly induction (weeks 1-4), then weekly (weeks 5-8), then every 1-2 weeks maintenance
- Half-life
- ~7-12 hours
- FDA indications
- Treatment-resistant depression (with an oral antidepressant, or as monotherapy — FDA-approved 2025); MDD with acute suicidal ideation
- Key adverse effects
- Dissociation (during dosing), sedation, dizziness, nausea, transient BP elevation. Abuse/diversion risk.
Black box: Sedation, dissociation, abuse potential, suicidal thoughts in young patients. REMS required — must be administered in certified healthcare setting with 2-hour monitoring.
Requires REMS-certified clinic. 2-hour observation after each dose. Patient cannot drive same day. Rapid antidepressant effect possible within hours. Cost and access constraints significant.
Esketamine is the S-enantiomer of ketamine, a non-competitive NMDA receptor antagonist. Block NMDA receptors and a counterintuitive cascade follows: glutamate surges, AMPA receptor activation rises, brain-derived neurotrophic factor (BDNF) is released, and rapid synaptogenesis occurs over hours. The synapses themselves remodel quickly — what SSRIs do gradually over weeks via different downstream effects, NMDA antagonism does fast.
Esketamine is the S-enantiomer of ketamine — an NMDA-antagonist antidepressant whose glutamatergic mechanism produces rapid effect outside the monoamine framework.
Mechanism note: Esketamine's value is rapid, mechanism-distinct antidepressant effect in TRD; its constraints are the monitored-administration requirement and limited durability without maintenance.
The clinical experience for the patient is unmistakable. After intranasal administration of 56 or 84 milligrams, the patient enters a brief altered state — dissociation, sometimes mild euphoria, transient blood pressure elevation, occasional sedation. The acute experience lasts roughly two hours, during which the patient must remain in the clinic under monitoring. By the next day, many patients describe a substantial mood lift — often the first time in months they have felt like themselves.
That experience is also why esketamine cannot be self-administered. The REMS — Risk Evaluation and Mitigation Strategy — requires that every dose be given in a certified clinic with monitoring, with the patient observed for at least two hours, with blood pressure checks, and with confirmation that the patient does not drive home. The infrastructure cost is substantial: a certified clinic, monitored space, dedicated time per patient. The patient cost is substantial: clinic visits twice a week for four weeks of induction, then weekly for four weeks, then every one to two weeks for maintenance.
Indications are specific. Treatment-resistant depression — failure of at least two adequate prior antidepressant trials — is the primary indication, with esketamine added to an ongoing oral antidepressant rather than replacing it. The second indication is major depressive disorder with acute suicidal ideation or behavior. Esketamine is the only FDA-approved antidepressant specifically labeled for that use, reflecting its rapid effect on suicidality in trial data.
Adverse effects center on the acute dosing experience. Dissociation — the patient feels disconnected from body or surroundings — is expected and time-limited. Sedation. Dizziness. Nausea. Transient blood pressure elevation. Anxiety. Most patients tolerate the acute effects; some find them intolerable.
Abuse potential is real — esketamine is a Schedule III controlled substance because ketamine has recreational use, and the REMS partly addresses diversion risk. The clinic-only administration model is itself a safety design.
Cost and access are the constraints that shape who actually gets esketamine. Insurance coverage has improved since approval but remains inconsistent. Geographic access is limited — certified clinics are concentrated in urban areas. For the patient with treatment-resistant depression who has insurance support and clinic access, esketamine is a genuine alternative to ECT, with a different burden profile and a different mechanism.
- Cost
- $590-885 per dose. ~$5,000-7,000/month induction; ~$3,000+/month maintenance.
- Generic status
- Brand-only Spravato. No generic anticipated.
- Formulary typical
- Specialty tier with REMS infrastructure requirement. Increasingly covered for FDA indications with PA documenting prior failures.
- Access friction
- REMS clinic certification required. Patient must be evaluated and treated only at certified site. 2-hour post-dose monitoring per dose. No driving same day. Substantial clinic-time investment.
Prescriber tip: Spravato Connect (Janssen patient support) helps navigate insurance, REMS, and patient costs. Plan for the 8 weeks of twice-weekly visits as part of the clinical commitment.
Esketamine is the first of what is likely to be a wave of rapid-acting antidepressants targeting the glutamate system. The longer-term answer about how it fits into the treatment ladder is still emerging.